This is a editors pick interview with postdoctoral researcher Lykke Midtbøll Ørnbjerg, MD, PhD, explaining the key content of the scientific publication from EuroSpA by Ørnbjerg et. al:

“Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care”.

You can read the original manuscript published in The Journal of Rheumatology in 2024 here:
https://www.jrheum.org/content/early/2024/02/09/jrheum.2023-0764

The original work was financially sponsored by Novartis.

Plain language summary EuroSpA publication 2.2, interview with Lykke Ørnbjerg:

This is a plain language summary interview of postdoctoral researcher Lykke Midtbøll Ørnbjerg, MD, PhD, explaining the key content of the scientific publication from EuroSpA by Ørnbjerg, Rugbjerg et. al:

One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission with Routine Care Tumor Necrosis Factor Inhibitor Treatment”.

You can read the original manuscript published in The Journal of Rheumatology in 2023 here: https://www.jrheum.org/content/early/2023/01/10/jrheum.220459.long

The original study was financially sponsored by Novartis.